Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Unió Europea - noruec - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaksiner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Nuvaxovid Unió Europea - noruec - EMA (European Medicines Agency)

nuvaxovid

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.

Pirfenidone axunio (previously Pirfenidone AET) Unió Europea - noruec - EMA (European Medicines Agency)

pirfenidone axunio (previously pirfenidone aet)

axunio pharma gmbh - pirfenidone - idiopatisk lungefibrose - immunsuppressive - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Pirfenidone Sandoz 801 mg Noruega - noruec - Statens legemiddelverk

pirfenidone sandoz 801 mg

sandoz - københavn - pirfenidon - tablett, filmdrasjert - 801 mg

Pirfenidone Sandoz 267 mg Noruega - noruec - Statens legemiddelverk

pirfenidone sandoz 267 mg

sandoz - københavn - pirfenidon - tablett, filmdrasjert - 267 mg

Qdenga Unió Europea - noruec - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaksiner - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Pirfenidone Viatris Unió Europea - noruec - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressive - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Bimervax Unió Europea - noruec - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaksiner - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Pirfenidone Newbury 267 mg Noruega - noruec - Statens legemiddelverk

pirfenidone newbury 267 mg

newbury pharmaceuticals ab - pirfenidon - tablett, filmdrasjert - 267 mg

Pirfenidone Newbury 801 mg Noruega - noruec - Statens legemiddelverk

pirfenidone newbury 801 mg

newbury pharmaceuticals ab - pirfenidon - tablett, filmdrasjert - 801 mg